ZD 7717
Latest Information Update: 08 Feb 2008
At a glance
- Originator AstraZeneca
- Class Anti-inflammatories
- Mechanism of Action 5-lipoxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Inflammation
Most Recent Events
- 08 Feb 2008 Discontinued - Preclinical for Inflammation in United Kingdom (unspecified route)
- 07 Apr 1999 Merger of Zeneca and Astra to form AstraZeneca completed
- 07 Sep 1998 No-Development-Reported for Inflammation in United Kingdom (unspecified route)